Gaudensia Mutua is the clinical trials team leader at the Kenya AIDS Vaccine Initiative (KAVI) Institute of Clinical Research (KAVI-ICR). She joined the organisation in 2004 and has conducted HIV and Ebola vaccine as well as HIV drug trials. Her primary area of scientific interest is in the development of new biomedical preventive methods against HIV. She also has a passion for working with and empowering communities to participate in medical research. She has worked with communities within the broad HIV risk spectrum including discordant couples and male and female sex workers. Her current focus is to engage adolescent girls and young women in HIV biomedical preventive trials. Her interest is informed by the fact that in Kenya, this group accounts for approximately 20% of all new infections. Developing targeted interventions to reduce new infections in this population is on the critical pathway towards reducing the burden of disease in Kenya.